Heartflow Inc. upped the price of shares in its IPO for a second time to $19 on Aug. 7 before opening on the Nasdaq as “HTFL” ...

Quantumpharm Inc., known as Xtalpi Inc., announced receiving $51 million up front from a potential $5.99 billion deal with ...

Minghui Pharmaceutical Ltd. announced it is raising $131 million in a pre-IPO financing round Aug. 7. The funds will be used to advance its cancer and inflammatory disease pipeline, which include a PD ...

The difference between the origin of Alzheimer's disease (AD) and its symptoms is an obstacle to finding effective treatments. Scientists focused on amyloid-β (Aβ) plaques and tau aggregates to slow ...

The U.S. Federal Trade Commission (FTC) reported Aug. 6 that it will try to block Edwards Lifesciences Corp.’s proposed ...

A federal appeals court opened the door Aug. 6 for an amended class-action lawsuit alleging that Astrazeneca plc, Eli Lilly ...

Location, location, location. While location is as important in manufacturing as it is in buying a home, it could become even ...

A management-led syndicate of prominent investors acquired a majority stake in Histosonics Inc. that values the company at ...

With half-year industry financings down 59% from last year, and a U.S. administration supportive of cryptocurrencies, ...

Infectious disease biopharma stocks bounced back in June and July, with the BioWorld Infectious Disease Index (BIDI) closing July up 4.34%. This marked a sharp reversal from earlier in the year, as ...

Hefei Institutes of Physical Science Chinese Academy of Sciences has synthesized phosphoglycerate kinase 1 (PGK1) inhibitors reported to be useful for the treatment of inflammatory bowel disease.

Nitrogen-containing heteroaromatic-based inhibitors for cytochrome P450 (CYP) in various species contain a crucial coordination between the nitrogen atom and the heme iron. Previous studies suggested ...